CD33 and acute myeloid leukemia: With the advent of eight other newly FDA-approved drugs for treatment of AML, the isocitrate dehydrogenase (IDH) inhibitors Ivosidenib and Enasidenib, the FMS-like tyrosine kinase 3 (FLT3) inhibitors Midostaurin and Gilteritinib, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin (GO), CPX-351, the hedgehog signaling pathway inhibitor Glasdegib, and the oral HMA CC-486, the answer to the question how to treat elderly patients has become more complicated (Table 1).